Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

AFFiRiS AG, corporate

AFFiRiS AG,

27.04.2021 - 09:03:02

AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference

and follow us on LinkedIn and Twitter.Contact AFFiRiS AG: Dr. Cornelia Kutzer E cornelia.kutzer@affiris.com W www.affiris.comMedia contact: MC Services AG Julia Hofmann, Europe: P +49 89 210228 0 Dr. Erica Fiorini, USA: P +1 914 310-8172 E affiris@mc-services.euAbout specific immunotherapies:https://affiris.com/approach/#overview-of-sait

About neurodegenerative diseases:https://affiris.com/neurodegenerative-diseases/

About Huntington's disease:https://affiris.com/neurodegenerative-diseases/#huntingtons-disease

27.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1188331??27.04.2021?

@ dgap.de